2021-03-23

Immune Therapeutics, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Immune Therapeutics, Inc..

Immune's lead program, bertilimumab, is a first-in-class, human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. 2014-08-19 2018-07-17 Immune Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock - read this article along with other careers information, tips … 2019-02-19 2016-09-07 Immune Pharmaceuticals Inc. Up to 123,333,333 Shares of common stock . Our common stock may be subject to the “penny stock” rules of the SEC, Immune Pharmaceuticals Inc. Announces Pricing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants October 19, 2017 09:00 AM Eastern Daylight Time Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of … On June 23, 2014, the current holders of 4,509 shares of Series C 8% Preferred Stock (the “Preferred Stock”) of Immune Pharmaceuticals Inc.(the “Company”), representing more than a majority of the outstanding Preferred Stock on June 23, 2014, agreed to amend the Company’s Corporation’s Certificate of Designation of Preferences, Rights and Limitations of Series C 8% Convertible Interactive chart of historical net worth (market cap) for Immune Pharmaceuticals (IMNPQ) over the last 10 years.

Immune pharmaceuticals inc common stock

Immune Pharmaceuticals (PK) (IMNPQ) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 2019-11-06 sec.gov - PROSPECTUS SUPPLEMENT NO. 8 (TO PROSPECTUS DATED APRIL 25, 2014) Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. 333-195251 Immune Pharmaceuticals Inc. 7,293,242 Shares of Common Stock This prospectus supplement No. 8 supplements and amends the prospectus dated April 25, 2014, as supplemented … Köp aktien Immune Pharmaceuticals Inc (IMNPQ). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Immune Pharmaceuticals Inc – COMMON STOCK PURCHASE AGREEMENT (February 3rd, 2017)COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2017 by and between IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of 3,450,000 units, with each unit consisting of one … Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten, registered public offering.

2006. Proposal 4 - Ratification of the Reverse Stock Split passes with shareholder Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a Immune Pharmaceuticals' Common Stock Approved for Trading on IMMUNE Pharmaceuticals Inc. to Present at 12th Annual BIO Investor ACTINIUM PHARMACEUTICALS INC ALPINE IMMUNE SCIENCES INC ALTUS MIDSTREAM COMPANY - CLASS A COMMON STOCK.

Immune Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock - read this article along with other careers information, tips and advice on BioSpace

2013. Namnändring från Epicept Corp till Immune Pharmaceuticals Inc. 21 augusti. 2020-03-26 · Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings results on Tuesday, May, 15th.

Catabasis Pharmaceuticals, Inc. Common Stock (CATB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Immune Pharmaceuticals net worth as of March 15, 2021 is $0B . 2014-11-20 NEW YORK and HERZLIYA PITUACH, Israel, Nov. 19, 2014 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced that it is proposing to offer shares of its common stock and Stock Ticker Lookup.

For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Immune Therapeutics, Inc.. * On March 22 co entered into a common stock purchase agreement with HLHW IV LLC * Immune Pharmaceuticals Inc- co has right to sell to buyer up to $1.6 million shares of company's common stock Immune Pharmaceuticals Inc – COMMON STOCK PURCHASE AGREEMENT (February 3rd, 2017)COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2017 by and between IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). The proposed merger plan will separate the Immune Pharmaceuticals LLC (In chapter 7) into the surviving entity that will not be subject to chapter 7 bankruptcy. Holders of common stock under this structure will retain a shareholding in the surviving public company and will be afforded as such shareholder rights in the new operating
Valutaväxling västervik

Klicka här för att följa aktiekursen i realtid Immune Pharmaceuticals Inc – COMMON STOCK PURCHASE AGREEMENT (February 3rd, 2017)COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2017 by and between IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). Immune Pharmaceuticals Inc. (NasdaqCM: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the closing of its previously announced underwritten public offering of 3,450,000 units, with each unit consisting of one … Immune Pharmaceuticals Inc. (NASDAQ: IMNP; "Immune" or "the Company"), a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today announced the pricing of its previously announced underwritten, registered public offering. IMMUNE PHARMACEUTICALS INC : News, information and stories for IMMUNE PHARMACEUTICALS INC | Nasdaq: | Nasdaq. Stock quotes are provided by Factset, Morningstar and S&P Capital IQ NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of the Company's common stock at a … Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock.

2013. Namnändring från Epicept Corp till Immune Pharmaceuticals Inc. 21 augusti.
Baker jazz festival

Stock Ticker Lookup. Search / Go. Form S-1/A Immune Pharmaceuticals Inc [Amend] General form for registration of securities under the Securities Act of 1933. SEC.report. IMMUNE PHARMACEUTICALS INC. Form S-1/A (Filer) Published: 2018-12-19 17:31:58 Submitted: 2018-12 …

4,019.87. NASDAQ.